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Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible
for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find
further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4mg b.d. They were followed clinically and
with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are
induced by this treatment (peroxisome proliferator-activated receptor g (PPARg), adipsin and fatty acid binding protein) was
determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to
progression was 6 months (2 – 16 months), with one patient still on treatment. We did not see any significant change in histologic
appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not
result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas.
Increased PPARg activity does not correlate with the clinical evolution.
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Soft-tissue sarcomas are a group of mesodermal tumours
encompassing many histotypes. Liposarcomas have a peak
incidence between age 50 and 65 years. Several subtypes exist,
ranging from low- to high-grade malignancy (well-differentiated-,
myxoid-, round cell-, pleomorphic-, mixed- and dedifferentiated-
type liposarcomas). Large tumours can consist of more than one
liposarcoma subtype, thus containing better types of differentia-
tion (Meis-Kindblom et al, 2001). By genetic analysis, a
characteristic t(12;16) translocation has been found for the
myxoid/round cell subtypes, generating a TLS-CHOP fusion
protein (Crozat et al, 1993; Knight et al, 1995). The exact function
of this transcript remains to be elucidated. Several forms of this
fusion protein have been described, but none of them seems to be
of prognostic value. A minority of these liposarcomas show a
different translocation, t(12;22), producing the EWS-CHOP fusion
transcript (Antonescu et al, 2001). Well-differentiated or dediffer-
entiated liposarcomas are characterised by supernummery ring
and/or giant marker chromosomes with amplified sequences of
chromosomal region 12q (Dei Tos, 2000).
Being notoriously resistant to chemo- and radiotherapy, the
major prognostic factors in the treatment of liposarcomas are their
resectability and grade. Metastatic liposarcoma is hardly curable.
However, the gain in knowledge about the molecular biology of the
normal differentiation of lipocytes has opened new treatment
perspectives. The peroxisome proliferator-activated receptor-g
(PPARg) is a nuclear receptor that has been identified as a key
player in the terminal differentiation of the adipocyte lineage
(Tontonoz et al, 1994a). It forms a heterodimeric complex with the
retinoid X receptor a that binds to specific DNA recognition sites
and regulates the transcription of adipocyte-specific genes
(Tontonoz et al, 1995). Ectopic expression and activation of
PPARg in human fibroblasts induces a complete adipocytic
phenotype (Tontonoz et al, 1994b). Several ligands for PPARg
have been identified, both natural and synthetic (Vamecq and
Latruffe, 1999). The thiazolidinedione class of drugs, which are
oral antidiabetics, has been shown to be agonist ligands for PPARg
(Lehmann et al, 1995). Treatment of liposarcoma cells in culture
with pioglitazone has induced terminal differentiation of these
cells (Tontonoz et al, 1997). In 1999, a clinical study with
troglitazone showed evidence for differentiation of liposarcomas in
vivo in three patients, assessing histological, biochemical, radi-
ological and biological parameters (Demetri et al, 1999).
Based on these data, we followed nine liposarcoma patients in a
phase II trial with rosiglitazone and documented clinical,
histological and biological tumour parameters during the treat-
ment.
PATIENTS AND METHODS
Patients and trial design
To be included in the study, patients had to have histologically
confirmed liposarcoma; advanced (unresectable) disease that was
measurable; prior surgery, chemotherapy or radiotherapy was
allowed; a WHO performance status of 0, 1 or 2 and a life
expectancy of at least 3 months. After obtaining an informed
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www.bjcancer.comof 4mg b.d. Patients were seen at the outpatient department at
baseline, at 6, 12, 20 and 32 weeks and at 1 year. CT scan imaging
was performed at the same intervals to follow the evolution of the
disease. Progressive disease was defined as a tumour volume
increase of 100%, instead of the classical WHO criterion of 50%.
This large cutoff was allowed because in vitro redifferentiated
liposarcoma tissue has an increased cellular volume due to the
intracellular accumulation of lipid (Tontonoz et al, 1997). Tumour
sampling by CT- or ultrasound-guided needle biopsy (with a
spring-driven device, supplied with a 14-gauge biopsy needle
yielding biopsies of 1.9cm in length) was also performed at the
same intervals except at 20 weeks.
Tumour tissue analysis
Biopsies were obtained for routine histologic staining with
haematoxylin and eosin, molecular analysis and cytogenetics.
Conventional classification of the histologic subtype was per-
formed by a single sarcoma specialist pathologist (RS). Staining for
PPARg was not routinely performed because no reliable antibody
was at hand. Molecular analysis to quantify mRNA levels was
performed by Taqman technology, following the manufacturer’s
instructions. This technique consists of two steps, namely an RT –
PCR and the annealing of a fluorescently labelled probe between
the two PCR primers. After processing, this probe yields a
measurable signal and gives an exact figure that represents the
level of a certain mRNA molecule in relation to an internal control
molecule, glyceraldehyde-3-phosphate dehydrogenase (GADPH).
The measured mRNA molecules included GADPH, PPARg, adipsin
and FABP. The forward and reverse primers were 50-agcctcaagat-
catcagcaatg and 50-atggactgtggtcatgagtcctt with the probe 50-
ccaactgcttagcacccctggcc for GADPH; 50-accccctgttgtgttttcca and
50-aatgggcttcacattcagcaa with the probe 50-atgtgcttccccagaccgccc
for PPARg;5 0-ccaagcgcctgtacgacgt and 50-agcaggaggtcgtggtcgat
with the probe 50-ctccgcgcagtgccccacc for adipsin and 50-tgtgca-
gaaatgggatggaaa and 50-acgcattccaccaccagttt with the probe 50-
tcaaccaccataaagagaaaacgagagggatga for FABP.
Cytogenetic analysis was performed to identify t(12;16) translo-
cations, typical for myxoid/round cell liposarcomas. Chromosome
metaphases were obtained after short-term culture of a primary
tumour sample, utilising standard procedures. G-banded chromo-
somes were evaluated and classified according to the International
System of Human Cytogenetic Nomenclature (Mitelman, 1995, 37/
id).
RESULTS
In all, 12 patients were entered onto the study. Two patients
became rapidly progressive and could not have a first control
biopsy. One patient developed hepatotoxicity, which normalised
after cessation of therapy, upon which the treatment was stopped.
Nine patients were eligible and evaluable for response. Their
characteristics are presented in Table 1. The mean age at diagnosis
of the liposarcoma and at the start of rosiglitazone treatment was
50 and 58 years, respectively. Six patients had myxoid/round cell
liposarcomas and three of these had the t(12;16) translocation that
characterises this subtype. The other histological subtypes were
two dedifferentiated and one well-differentiated liposarcoma.
The median treatment duration was 5.5 months (2 – 16 months
with one patient still on treatment), with at least one biopsy taken
while on treatment.
The histopathological appearance of the tumour did not show
any sign of redifferentiation by routine haematoxylin and eosin
staining. An important variable was the problem of sampling error
during the needle biopsies. As liposarcomas are often phenotypi-
cally heterogeneous, this can render reproducible sampling
impossible. To check the cellular proliferation rates, expression
of the Ki-67 nuclear antigen was assayed consecutively in tumour
samples of eight patients (Figure 1). The proliferation rate of the
tumour cells was, as expected in these slowly growing tumours,
very low at baseline. Although in more than half of the patients a
decline was noted, it was not possible to detect any significant
difference.
Next, we examined the gene expression level of PPARg, adipsin
and fatty acid binding protein, three genes that are specifically
linked to adipocytic differentiation. This accurate method would
allow a proof of principle of the treatment and a correlation with a
potential response. Biopsy material of eight patients could be
evaluated. Only one patient, no. 4, had a significant but
inconsistent upregulation of all three genes after 6 and/or 12
weeks. This patient had a dedifferentiated liposarcoma and was
treated with rosiglitazone for 10 weeks until progression was
noted. One other patient, no. 1, had upregulation of only one gene
product, adipsin, after 12 weeks of treatment. This patient had a
myxoid liposarcoma and continued medication for 6 months
before progression was noted. For the six other patients no rise in
gene expression level could be found (Figure 2).
Table 1 Patient characteristics
Patient no. (age at









1 (60 – F) Myxoid N RP Surgery/CT 72 6 months
2 (64 – M) Myxoid/round cell Y Thigh Surgery/CT 74 4 months
3 (55 – M) Dedifferentiated ND RP Surgery/CT 61 8 months
4 (61 – M) Dedifferentiated ND RP Surgery/CT 63 10 weeks
5 (53 – M) Myxoid/dedifferentiated N RP Surgery 55 2 months
6 (35 – F) Myxoid/round cell Y Thigh Surgery/RT 63 416 months
7 (37 – M) Myxoid/round cell Y RP Surgery/RT 39 2 months
8 (46 – M) Myxoid/round cell N Thigh Surgery/CT/RT 48 5 months
9 (41 – F) Well differentiated ND RP Surgery/RT 46 9 months






























Figure 1 Ki-67 proliferation-associated antigen expression during
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The strategy of activation of PPARg to induce differentiation or
maturation in cells is increasingly receiving attention in cancer
treatment during the last few years. It is an attractive model in
anticancer therapy, because it has a targeted molecular basis and
acts with little side effects, in contrast to chemotherapy. Since
adipose tissue has the highest expression of PPARg, liposarcomas
have a theoretical advantage using this treatment as compared to
other tumours. Mainly in vitro studies offer substantial evidence
for the redifferentiation mechanism by stimulating PPARg. So far
one clinical study with three patients with liposarcomas has shown
some effect, albeit with a short follow-up period.
In this phase II study, we sought to find further arguments for
the efficacy of this treatment for a longer period of time. We
collected clinical, histopathological and biological data of nine
patients that were treated with rosiglitazone. However, our results
were disappointing. The mean progression free survival period was
5.5 months, realising that an uncommon definition of progressive
disease was used, namely a 100% tumour volume increase.
Morphologically, no convincing sign of redifferentiation could be
detected. Stainings of the Ki-67 antigen did not show a significant
decrease, mainly because of the very low baseline values in these
tumours. An important effort was made to determine the
molecular stimulation of PPARg by measuring the gene products
of its activation at the transcriptional level. Since we saw a limited
but significant upregulation of gene expression in two patients, we
concluded that our methodology was correct and that it was
possible to activate PPARg in vivo. However, we could not find a
correlation between this upregulation and a clinical response in
our patients.
Several remarks can be made to these results. This is the first
clinical trial that uses rosiglitazone as a stimulator of PPARg, while
other clinical trials have used troglitazone. Rosiglitazone has the
theoretical advantage of being more potent than troglitazone
(Goldstein, 2000). Hepatotoxicity is seldom seen with rosiglitazone
in comparison with troglitazone. Nevertheless, we had to withdraw
one patient from the trial due to elevated liver transaminases.
By showing a biological effect in two patients, we could prove at
the molecular level that this drug indeed activates PPARg in vivo.
Why we did not see a rise of the gene products in the other patients
is not clear. A possible explanation could be an unresponsive
PPARg due to an inactivating mutation. Such mutations have been
described in sporadic colon carcinomas (Sarraf et al, 1999) and
thyroid carcinomas (Kroll et al, 2000) but, to our knowledge, not
in liposarcomas. Other transcriptional errors can of course also be
present in these malignant cells.
More important is the fact that the apparent biological
activation of PPARg in these two patients had no clinical or
histopathological counterpart. Stimulation of PPARg has been
shown to lead to apoptosis in a colon cancer cell line (Chen et al,
2002). However, treatment of patients with metastastic colon
cancer with troglitazone is ineffective (Kulke et al, 2002). The
anticancerous effect of thiazolidinediones has also been shown to
be independent from PPARg activition using PPARg
 /  embryonic
stem cells, showing inhibition of translation initiation (Palakurthi
et al, 2001) as the antitumoral activity. And recently rosiglitazone
was proven to inhibit tumour growth and metastasis by inhibiting
angiogenesis (Panigrahy et al, 2002). These data are in contra-
diction with the redifferentiation model by the activation of the
receptor, but can explain a possible antitumoral effect of this drug.
Human malignancies very rarely harbour mutations of the
PPARg gene (Ikezoe et al, 2001, 38/id). This implies that aiming at
PPARg as a specific antitumoral target is not likely to be successful.
As for liposarcomas, more knowledge needs to be gained about the
fundamental biologic alterations, especially about the translocation
that characterises some of the subtypes.
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Figure 2 Relative gene expression of PPARg, fatty acid binding protein
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